Mercados españoles cerrados en 6 hrs 37 min

UCB SA (UCBJF)

Other OTC - Other OTC Precio demorado. Divisa en USD
Añadir a la lista de favoritos
102,000,00 (0,00%)
Al cierre: 11:26AM EST

UCB SA

AllEe de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
https://www.ucb.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo8600

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Jean-Christophe TellierCEO & Executive Director3,62MN/A1959
Ms. Sandrine Dufour CFAExecutive VP & CFO & Chief Corporate DevelopmentN/AN/A1966
Dr. Kirsten Lund-Jurgensen Ph.D.Executive Vice President of Supply & Technology SolutionsN/AN/A1960
Dr. Dhavalkumar D. Patel M.D., Ph.D.Executive VP & Chief Scientific OfficerN/AN/A1961
Mr. Jean-Luc FleurialExecutive VP & Chief Human Resources OfficerN/AN/A1965
Prof. Iris Low-FriedrichExecutive VP, Chief Medical Officer and Head of Development & Medical Patient Value PracticesN/AN/A1960
Mr. Emmanuel CaeymaexExecutive VP of Immunology Solutions & Head of USN/AN/A1969
Ms. Caroline VancoillieChief Accounting Officer, Head of Group Finance & CFO of Patient Value FunctionsN/AN/AN/A
Antje WitteHead of Investor RelationsN/AN/AN/A
Ms. Denelle J. Waynick Johnson J.D.Executive VP & General CounselN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Gobierno corporativo

El ISS Governance QualityScore de UCB SA, a día 1 de febrero de 2024, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 3; Derechos de los accionistas: 1; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.